Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:12 AM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom mRNA cancer therapy. Patients receiving the treatment with Keytruda went longer without cancer returning or spreading. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:07 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:02 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a major clinical milestone that drove a 177% share surge. This represents a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:57 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:52 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with shares surging 177%, indicating a material positive catalyst and improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:47 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:44 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company, supporting a BUY operation.